Drugmakers Increase Prices on Over 250 Medications

Key Points:

1. Over 250 branded drugs saw price increases in the U.S., including Paxlovid and cancer therapies.
2. Median price hike was 4.5 percent, triggering renewed debate over drug affordability.

Pharmaceutical companies have raised prices on more than 250 branded medications in the United States, including high-profile treatments like Pfizer’s Paxlovid, Bristol Myers Squibb’s CAR T-cell therapies, and multiple vaccines produced by Sanofi. The median price increase stands at 4.5 percent, and while most hikes were under 10 percent, the number of drugs affected is substantial. This marks a jump from the 140 drugs whose prices were raised at the end of the previous year. These increases reflect changes to list prices and do not account for behind-the-scenes rebates or confidential discounts negotiated with pharmacy benefit managers. Experts believe that recent legislation expanding penalties for annual price increases may be encouraging companies to introduce new medications at higher starting prices. Industry insiders say this is a strategic pivot rather than a temporary trend. The price hikes have reignited national discussions around drug affordability and access to life-saving therapies. Pfizer’s Paxlovid, for example, saw a moderate 3 percent bump, while Bristol Myers Squibb increased prices on Abecma and Breyanzi by 6 and 9 percent respectively. Sanofi implemented price increases on several of its widely used vaccines as well. Patient advocacy organizations and elected officials have responded with concern, questioning how these costs impact everyday Americans. On the other side, pharmaceutical executives continue to argue that price increases are essential to support costly research and development efforts. Observers note that although more drugs are being affected, the scale of individual price hikes has moderated compared to previous decades. This could reflect a longer-term strategy to balance investor expectations with growing public and political scrutiny.

Relevant reading: Pfizer, BMS and more ring in 2025 with fresh round of drug price hikes

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.